American Academy of Optometry

Americans are Frustrated by Unexpected Blurry Near Vision Issues, a New Survey Reveals

Retrieved on: 
Monday, September 27, 2021
People, Myopia, News, Epidemic, Failure, Instagram, Risk, Annual report, Pandemic, Security (finance), Health, Private Securities Litigation Reform Act, Ageing, Retina, U.S. Securities and Exchange Commission, Virology, Frustration, Patient, American Academy of Optometry, Gastroenterology, LinkedIn, Diabetic retinopathy, YouTube, ECP, Twitter, American Academy, Acquisition, Presbyopia, Prevalence, Reading, Central retinal vein occlusion, Zoom, COVID-19, Research, Neuroscience, Glaucoma, AbbVie, Industry, Health insurance, Online gambling

Despite the high prevalence of near vision issues like presbyopia, these challenges can still come as a surprise to people with difficulty seeing up close.

Key Points: 
  • Despite the high prevalence of near vision issues like presbyopia, these challenges can still come as a surprise to people with difficulty seeing up close.
  • There are options available to manage near vision issues, but they can come with challenges of their own.
  • Additionally, for many adults, blurry near vision may impact the activities they enjoy most.
  • The online Blurry Near Vision survey, commissioned by Allergan and conducted by Wakefield Research, was fielded from August 2 August 9, 2021, to 1,000 nationally representative U.S. adults ages 40 55 who reported having near vision issues.

jCyte® Announces Appointment of Dr. Rebecca Kammer as Vice President of Clinical Operations

Retrieved on: 
Tuesday, September 21, 2021
Health, FDA, General Health, Research, Science, Optical, Biotechnology, Clinical trial, Research, European Medicines Agency, Higher education, FDA, Patient, RP, American Academy of Optometry, Annual general meeting, Association, Health, Optical engineering, American Academy, Education, University, Company, Rehabilitation, Associate, Leadership, Retinitis pigmentosa, University of La Verne, Technology, Azusa Pacific University, ARVO, Laverne, Doctor of Philosophy, Orphan drug, Department, Medical device, Medicine, Pharmaceutical industry

jCyte, Inc ., a private biotechnology company dedicated to improving the lives of patients with retinal degenerative diseases, announced today the continued expansion of the Companys leadership team with the appointment of Dr. Rebecca Kammer as Vice President of Clinical Operations.

Key Points: 
  • jCyte, Inc ., a private biotechnology company dedicated to improving the lives of patients with retinal degenerative diseases, announced today the continued expansion of the Companys leadership team with the appointment of Dr. Rebecca Kammer as Vice President of Clinical Operations.
  • Dr. Kammer will also be responsible for the creation, refinement, and supervision of clinical trial endpoints and other assessments conducted at the centralized jCyte Low Vision Testing Center.
  • Dr. Kammer joins jCyte with over 20 years of experience in academia, low vision patient care, clinician education, endpoint development, and professional consulting.
  • The addition of Dr. Kammer brings to jCyte a worldwide expert in the field of low vision clinical and outcomes research, said Dr. Shannon Blalock, Chief Executive Officer, jCyte.